PO

Polaris AI Pharma Corp.

A global supplier of generic APIs using AI to accelerate drug development.

041910 | KO

Overview

Corporate Details

ISIN(s):
KR7041910001
LEI:
Country:
South Korea
Address:
경기도 화성시 향남읍 발안공단로 25, 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Polaris AI Pharma Corp., formerly Estechpharma, is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs). The company specializes in the production of generic APIs, with a portfolio of approximately 40 products for various therapeutic areas, including anti-thrombotic, anti-inflammatory, and treatments for gastric ulcers and asthma. A key strategic focus is the integration of artificial intelligence into its research and development pipeline to predict the success of drug candidates and optimize clinical trial designs, thereby accelerating the development process. Polaris AI Pharma serves both domestic and international pharmaceutical markets and engages in joint research for innovative drug delivery systems.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Quarterly Report
[기재정정]분기보고서 (2025.03)
Korean 884.1 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-12 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 19.8 KB
2025-08-12 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 15.7 KB
2025-08-07 00:00
M&A Activity
[기재정정]주요사항보고서(유형자산양수결정)
Korean 20.0 KB
2025-08-01 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.5 KB
2025-07-07 00:00
M&A Activity
주요사항보고서(유형자산양수결정)
Korean 15.9 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 907.9 KB
2025-03-20 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.5 KB
2025-03-12 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 540.9 KB
2025-03-12 00:00
Audit Report / Information
감사보고서제출
Korean 19.4 KB
2025-03-05 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.4 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.9 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 118.6 KB
2024-12-16 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB

Automate Your Workflow. Get a real-time feed of all Polaris AI Pharma Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Polaris AI Pharma Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Polaris AI Pharma Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America
ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden
ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America
ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America
AAPG
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan
4886
Aspire Biopharma Holdings, Inc. Logo
Developing a nano-platform for rapid, sublingual delivery of reformulated medications.
United States of America
ASBP
ASSEMBLY BIOSCIENCES, INC. Logo
Clinical-stage biopharma developing small-molecule antivirals for herpes, HBV, and HDV.
United States of America
ASMB

Talk to a Data Expert

Have a question? We'll get back to you promptly.